Henlius 2024 Interim Results Investor Presentation

Henlius reported 2024 first-half revenue of RMB 2.7 billion with net profit of RMB 386 million, demonstrating sustainable profitability growth driven by strong sales of oncology products HLX10 and HLX02. The biopharmaceutical company expanded its global pipeline with FDA approvals for Phase 3 trials, in-licensing deals, and manufacturing capacity optimization exceeding 1,000 production batches.